NCT04813107Unknown1 期
A Phase I/II Open-Label Multicenter Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer (MIBC)
Jiangsu Yahong Meditech Co., Ltd aka Asieris2 个研究点 分布在 2 个国家目标入组 79 人开始时间: 2021年12月28日最近更新:
适应症
干预措施
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 79
- 试验地点
- 2
- 主要终点
- Adverse events (AE) and serious adverse events (SAE).
研究概览
简要总结
This trial is designed to evaluate the safety, efficacy, and biomarker response of APL-1202 in combination with tislelizumab as neoadjuvant therapy for patients with MIBC who are cisplatin ineligible or refuse cisplatin-based chemotherapy.
详细描述
This trial is an open-label, multi-center clinical study consisting of two periods: Phase Ⅰ and Phase Ⅱ. Phase I is a dose escalation study to determine MTD (maximum tolerated dose) and/or RP2D. Phase II is an expanded proof of concept (POC) study to evaluate the safety and efficacy of APL-1202 in combination with tislelizumab compared to tislelizumab alone as neoadjuvant therapy for MIBC as measured by pCR.
Phase Ⅰ and Phase Ⅱ both are divided into 3 periods: screening period, neoadjuvant therapy and follow-up period:
- The screening period is up to 4 weeks before the first doses of study treatments.
- During the neoadjuvant therapy, each patient will receive the combined treatment of tislelizumab and APL-1202 or tislelizumab alone, every 21 days as a dosing cycle for a total of 3 cycles of treatment prior to radical cystectomy.
- The follow-up period includes a safety follow-up at 4 weeks after radical cystectomy.
Phase Ⅰ: Dose-Escalation The dose escalation phase will assess the safety, tolerability, and pharmacokinetics of APL-1202 in combination with tislelizumab in MIBC patients. Results from this period will determine the RP2D of APL-1202 in combination with tislelizumab as neoadjuvant therapy for MIBC.
Patients enrolled in this phase must meet the following criteria: those with newly diagnosed MIBC for whom RC is planned, and who are cisplatin ineligible or refuse to receive cisplatin based neoadjuvant chemotherapy, and with calculated CrCl ≥ 50 mL/min (by Cockcroft-Gault equation).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Willing and able to provide written informed consent.
- •Age ≥ 18 years.
- •Histopathologically confirmed transitional cell carcinoma of the bladder. Patients with mixed histologies are required to have a dominant (i.e. > 50%) transitional cell pattern.
- •Radical cystectomy is planned (according to local guidelines).
- •Patients who refuse neoadjuvant cisplatin based chemotherapy or in whom neoadjuvant cisplatin based therapy is contraindicated. Contraindications to cisplatin is defined by meeting at least one of the following criteria:
- •Impaired renal function with calculated CrCl 30 to 59 mL/min (by Cockcroft-Gault equation).
- •Eastern Cooperative Oncology Group (ECOG) Performance Status
- •CTCAE v.5 Grade ≥2 audiometric hearing loss.
- •In the clinical judgement of the investigator, potential adverse effects from cisplatin-based neoadjuvant chemotherapy outweighs its benefits.
- •Clinical stage T2-T4a N0 M0 disease by CT (or MRI) (within 4 weeks of randomization).
- •Residual disease after transurethral resection of bladder (TURB) (surgical opinion, cystoscopy or radiological presence).
- •Availability of representative formalin-fixed paraffin-embedded (FFPE) tumor specimens or unstained slides, with an associated pathology report, and determined to be evaluable for tumor PD-L1 expression prior to study enrollment;
- •Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-
- •Adequate hematologic and end-organ functions:
- •Hemoglobin > 9.0 g/dL;
- •Absolute neutrophil count (ANC) > 1.5×109 /L;
- •Platelet count > 100×109 /L;
- •Serum bilirubin ≤ 1.5 x institutional upper limit of normal (ULN).
- •Aspartate aminotransferase (AST) /alanine aminotransferase (ALT) ≤ 2.5 x institutional upper limit of normal ULN.
- •CrCl (calculated using Cockcroft-Gault equation) ≥ 30 mL/min (calculated CrCl ≥ 50 mL/min in Phase Ⅰ: Dose-Escalation).
- •INR < 1.
- •This applies only to patients who are not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose.
- •Female patients should be surgically sterilized or post-menopausal or must agree to take effective contraceptive measures during the treatment. Male patients must be surgically sterilized or must agree to take effective contraceptive measures during treatment. Patients must continue to take contraceptive measures for 3 months after the investigational therapy was completed.
排除标准
- •Previous systemic therapy for bladder cancer.
- •Malignancies other than urothelial bladder cancer within 5 years prior to cycle 1, Day 1, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, or ductal carcinoma in situ of breast treated surgically with curative intent).
- •Evidence of measurable nodal or metastatic disease.
- •Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol or interpretation of results, including significant liver disease (such as cirrhosis, uncontrolled major seizure disorder, or superior vena cava syndrome).
- •Pregnant female patients. All female patients with a positive pregnancy test within 2 weeks prior to the first dose of study treatment will be excluded from the study.
- •Significant cardiovascular disease, such as New York Heart Association cardiac disease (more than Class II), myocardial infarction within 3 months prior to enrollment, unstable arrhythmias, or unstable angina.
- •Severe infections within 4 weeks prior to enrollment in the study including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia.
- •Major surgical procedure within 4 weeks prior to enrollment or anticipation of need for a major surgical procedure during the course of the study other than for diagnosis.
- •History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.
- •Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the tislelizumab or APL-1202 formulation.
- •History of autoimmune disease including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.
- •History of autoimmune-related hypothyroidism, unless on a stable dose of thyroid-replacement hormone.
- •History of idiopathic pulmonary fibrosis.
- •Uncontrolled Type 1 diabetes mellitus.
- •Uncontrolled hypercalcemia (> 1.5 mmol/L ionized calcium or calcium > 12 mg/dL or corrected serum calcium > ULN) or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or denosumab.
- •Prior allogeneic stem cell or solid organ transplantation.
- •Positive test for HIV.
- •Uncontrolled hepatitis infection.
- •Active tuberculosis.
- •Optic nerve disorders or with a history of optic nerve disorders.
- •Cataract or with a history of cataract.
- •Prior treatment with anti-programmed death-1 (PD-1), or anti-PD-L1 therapeutic antibody or pathway-targeting agents.
- •Patients taking regular oral steroids, above the allowed limit of 10 mg/day methylprednisolone/prednisone or analogues, for any reason. Patients must not have had steroids for 4 weeks prior to study entry.
- •Administration of vaccine within 4 weeks prior to enrollment or anticipation that such a vaccine will be required during the study.
- •Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 4 weeks prior to enrollment.
- •Treatment with systemic immunostimulatory agents within 4 weeks prior to enrollment.
研究组 & 干预措施
APL-1202 in combination with tislelizumab
Active Comparator
干预措施: APL-1202 in combination with tislelizumab (Drug)
Tislelizumab alone
Placebo Comparator
干预措施: Tislelizumab alone (Drug)
结局指标
主要结局
Adverse events (AE) and serious adverse events (SAE).
时间窗: 9 weeks
Adverse events (AE) and serious adverse events (SAE) in Phase Ⅰ(Dose-Escalation)
The rate of pathologic complete response (pCR) in Phase 2.
时间窗: 26 months
Pathological complete response (pCR) is defined as no microscopic evidence of residual disease in the bladder based on histological evaluation of the resected bladder specimen collected during cystectomy.
The RP2D of APL-1202 in combination with tislelizumab.
时间窗: 9 weeks
The RP2D of APL-1202 in combination with tislelizumab in Phase Ⅰ(Dose-Escalation)
次要结局
- Radiological response (RR).(26 months)
- Cmax(26 months)
- t1/2(26 months)
- Tumor mutation burdens (TMB) in pre- and post-treatment tumor tissues.(26 months)
- AUC(26 months)
- Cumulative amount in urinary excretion (Ae)(26 months)
- Tumor mutation burdens (TMB) in pre- and post-treatment urine cfDNA (cell free DNA).(26 months)
- cumulative fraction of dose in urinary excretion (Ae%)(26 months)
- Tumor mutation burdens (TMB) in pre- and post-treatment plasma ctDNA (circulating tumor DNA).(26 months)
- Tmax(26 months)
- PD-L1 protein expression levels in pre- and post-treatment tumor tissues.(26 months)
研究者
研究点 (2)
Loading locations...
相似试验
暂停
1 期
A Study of ABTL0812 in Pancreatic CancerPancreatic CancerNCT03417921Ability Pharmaceuticals SL60
已完成
1 期
A Study to Assess the Efficacy and Safety of ABTL0812Endometrial CancerSquamous Non-Small Cell Lung CancerNCT03366480Ability Pharmaceuticals SL103
终止
2 期
Evaluation of Votrient in AngiosarcomaAngiosarcomaNCT02212015Heidelberg University26
招募中
2 期
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal CancerHigh-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal CancerNCT05128825K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc310
已完成
2 期
A Study of Bevacizumab (Avastin) in Combination With Temozolomide (TMZ) and Radiotherapy in Paediatric and Adolescent Participants With High-Grade GliomaHigh Grade GliomaNCT01390948Hoffmann-La Roche124